#Sweden #Stockholm #Lecanemab #Eisai #BioArctic

New Clinical Data on Lecanemab at CTAD 2026

BioArctic AB, in collaboration with its partner Eisai, is gearing up to present pivotal new clinical and real-world findings about lecanemab (Leqembi®) during the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference. This significant event is scheduled to take place from November 16-19, 2026, in Boston.

The presentation will showcase insights garnered from both the Clarity AD study and the LEADER study, which investigate the use of lecanemab in different clinical settings across the United States. These analyses focus on its long-term safety and efficacy, particularly in early Alzheimer's disease patients.

Five-Year Insights from Clarity AD

One of the highlights of the presentations will be a comprehensive five-year follow-up data regarding lecanemab from the Clarity AD study. This study has been notable for providing one of the longest follow-up periods for any approved anti-amyloid therapy in Alzheimer's disease. Attendees can expect in-depth analysis and discussions on how treatment has impacted patients over this extended timeframe. The Clarity AD study’s dataset will include both core and extension phases, offering vital information on how lecanemab continues to influence patient outcomes over the years.

Real-World Considerations from the LEADER Study

Additionally, results from the LEADER study will shed light on how lecanemab has been utilized in real-world clinical practices since the drug's FDA approval. This retrospective multicenter study provides valuable insights into treatment patterns and outcomes across diverse US clinical settings three years post-approval. These findings are expected to inform healthcare professionals about the medications' practical implications and efficacy in everyday use.

Key analyses will delve into how lecanemab is treated against factors such as safety profiles and treatment persistence. The agenda also includes discussions on real-world safety concerning ARIA (Amyloid-Related Imaging Abnormalities) rates observed across various populations treated with lecanemab.

Presentations and Posters at CTAD

During the symposium, Eisai aims to present several oral and poster sessions on crucial data surrounding lecanemab. These sessions will cover topics such as the sex-based outcomes of lecanemab treatment and the implications of treatment with subcutaneous lecanemab administration. Attendees can expect to hear these new findings during high-profile oral sessions scheduled throughout the event.

Key Symposium Sessions

• - November 18: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter Retrospective Study (LEADER) in Diverse US Clinical Settings.
• - Ongoing Findings: New findings regarding long-term treatment outcomes and safety profiles will be shared, enhancing the existing knowledge about lecanemab.

Looking Ahead

BioArctic and Eisai’s continuous commitment between the ongoing research of lecanemab emphasizes hope for patients affected by Alzheimer's disease. With the growing body of evidence supporting lecanemab's efficacy, the upcoming presentations at CTAD are anticipated to further solidify its standing in Alzheimer's treatment options.

In summary, the CTAD 2026 conference will not only serve as a platform for presenting significant clinical data, but also an important opportunity for healthcare professionals to gather and discuss innovative findings that may shape the future of Alzheimer’s treatments.

As BioArctic and Eisai take the next steps in sharing their insights, the Alzheimer’s community eagerly awaits the results that can enhance understanding and improve patient care in real-world applications of lecanemab.